Topical Ripasudil

Phase 3

SStanford University

Topical Ripasudil is one of 2 therapeutic programs targeting Fuchs. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

FuchsActive, not recruiting

FuchsPhase 3

Active, not recruiting

Competition

Competitive Landscape

1 competitor in Fuchs

#DrugCompanyPhaseTrials

Ripasudil

KKowa Research Institute, Inc.

Phase 3

2 2

Topical Ripasudil

SStanford University

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 3Active, not recruiting

Fuchs

NCT05289661

Clinical

Trials by Indication[1]

Fuchs1 trial

Descemet Endothelial Thickness Comparison Trials (DETECT I & II)

Active, not recruiting·SStanford University·Phase 3·NCT05289661·160 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Topical Ripasudil. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Topical Ripasudil. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Stanford University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: SStanford University

Topical Ripasudil

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Fuchs1 trial

References

Drug Info

Quick Facts

Related News